Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 6/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532384 | 0.88 | SNCA (0.53) | HSD17B10SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL18228061 | 0.84 | SNCA (0.43) | SMN1; SMN2NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL4473651 | 0.81 | SNCA (0.47) | HSD17B10SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL18239747 | 0.81 | HTT (0.42) | SNCALPLLIPGIRAK4 | |
| SCHEMBL18230156 | 0.81 | SNCA (0.42) | SNCALPLLIPGIRAK4 | |
| SCHEMBL24478930 | 0.81 | SNCA (0.47) | HSD17B10SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL31689372 | 0.81 | SNCA (0.47) | HSD17B10SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL30469799 | 0.80 | SNCA (0.41) | SNCALPLLIPGIRAK4 | |
| SCHEMBL29081904 | 0.80 | SNCA (0.41) | SNCALPLLIPGIRAK4 | |
| SCHEMBL29981144 | 0.80 | LOXL2 (0.51) | NPC1RAB9ASNCAGAALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005113536-A2 | TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBOTT LABORATORIES | 2005-11-17 | — | — | US | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004101559-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | HSD17B10 2485/4885SMN1; SMN2 1498/4885NPC1 1872/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | HSD17B10 540/4885SMN1; SMN2 3245/4885NPC1 2220/4885 |
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | HRH3, HRH4, HRH2 | HSD17B10 3354/4885SMN1; SMN2 4849/4885NPC1 2680/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | HSD17B10 2805/4885SMN1; SMN2 1278/4885NPC1 3501/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | HSD17B10 2805/4885SMN1; SMN2 1278/4885NPC1 3501/4885 |
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | HSD17B10 2950/4885SMN1; SMN2 3690/4885NPC1 850/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | HSD17B10 4179/4885SMN1; SMN2 4269/4885NPC1 4106/4885 |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | HRH4, HRH3, HRH2 | HSD17B10 2518/4885SMN1; SMN2 2248/4885NPC1 1618/4885 |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | HSD17B10 509/4885SMN1; SMN2 4153/4885NPC1 3838/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | HSD17B10 1375/4885SMN1; SMN2 1943/4885NPC1 39/4885 |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | HRH3, HRH4, HRH2 | HSD17B10 3354/4885SMN1; SMN2 4849/4885NPC1 2680/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | HSD17B10 1375/4885SMN1; SMN2 1943/4885NPC1 39/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | HSD17B10 4179/4885SMN1; SMN2 4269/4885NPC1 4106/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | HSD17B10 1375/4885SMN1; SMN2 1943/4885NPC1 39/4885 |
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | HSD17B10 2950/4885SMN1; SMN2 3690/4885NPC1 850/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | HSD17B10 410/4885SMN1; SMN2 1645/4885NPC1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.